Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Vincristine · Marqibo Kit, Oncovin

Small molecule · Kills target cells, directed at microtubules · developed by Lilly

Approved FDA, Jul 1963

2 Registered trials

What is Vincristine?

Vincristine is a natural alkaloid that binds irreversibly to microtubules and spindle proteins, arresting tumor cells in metaphase. It also depolymerizes microtubules and interferes with cellular metabolism and biosynthesis. The drug is studied in acute lymphoblastic leukemia and high-grade B-cell lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Marqibo Kit, Oncovin, LCR, VCR, Leurocristine, Vincrystine
Drug type: Small molecule
Targets: microtubules
Mechanism: Kills target cells, directed at microtubules
Pathways: mitotic spindle formation, microtubule depolymerization
Therapy area: Oncology
Developer: Lilly
In trials of: ADCT, JAZZ
FDA status: Approved as Marqibo Kit, Oncovin (July 10, 1963), NDA014103
UNII: 5J49Q6B70F

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06738368	Phase 2	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Suspended	JAZZ
NCT05600686	Phase 2	Double-Expressor Lymphoma	Active not recruiting	ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Double-Expressor LymphomaT Acute Lymphoblastic Leukemia

Sources

NCI Thesaurus

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z